Open AccessWhat is new in the pathogenesis and management of erythema nodosum leprosum
Author(s) -
Ramesh M Bhat,
Tanvi Vaidya
Publication year - 2020
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/idoj.idoj_561_19
Subject(s) - medicine , thalidomide , dermatology , leprosy , erythema nodosum , lepromatous leprosy , intensive care medicine , immunology , disease , multiple myeloma
Erythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition. The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.